CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Evaluation of the Performance of the Cepheid Xpert HIV‐1 Viral Load Assay for Quantitative and Diagnostic Uses
-
1 2020
-
-
Source: J Clin Virol. 122:104214
[PDF-739.42 KB]
Details:
-
Alternative Title:J Clin Virol
-
Personal Author:
-
Description:Background
Cepheid’s Xpert HIV‐1 Viral Load (Xpert VL), a simplified, automated, single-use quantitative assay used with the GeneXpert System, is not FDA-approved.
Objectives
Using stored plasma, we conducted a study to assess the ability of Xpert VL to quantify viral load relative to the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 (Cobas VL) and to examine the use of the Xpert VL as a qualitative diagnostic test.
Study Design
Following HIV-1 viral stock dilutions, we conducted a probit analysis to identify the concentration where 95% of specimens had quantified VLs. We also examined Xpert and Cobas log VL correlation in linearity panels; compared the proportion of 220 seroconverter specimens with virus detected using McNemar’s test; and tested specimens from persons with untreated, established HIV-1 infection (n=149) and uninfected persons (n=497). Furthermore, we examined Xpert VL as a qualitative test in seroconverter specimens with early (n=20) and later (n=68) acute infections.
Results
At 1.80 log10 copies/mL, 95% of specimens had quantifiable virus using Xpert VL. Xpert and Cobas VLs were highly correlated (R2=0.994). The proportion of seroconverter specimens with virus detected using Cobas and with Xpert VL was not statistically different (p=0.0578). Xpert VL detected 97.9% of established infections, and specificity was 99.80% (95% CI 98.87%−99.99%). Xpert VL detected 90% and 98.5% of early and later acute infections, respectively.
Conclusions
If approved, Xpert VL could allow U.S. laboratories that cannot bring on large, complex testing platforms to conduct HIV monitoring. An approval for diagnostic use may provide timely identification of HIV infections.
-
Subjects:
-
Keywords:
-
Source:
-
Pubmed ID:31835210
-
Pubmed Central ID:PMC11089535
-
Document Type:
-
Funding:
-
Volume:122
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
